Biomarkers in Psychiatry – Are We Ready For Prime Time?-View Presentation

Video Transcription

Video Summary

The panel discussion centered around the potential of biomarkers in psychiatry, including their roles in diagnosing and predicting treatment responses in mental health disorders. Dr. Nina Kraguljak emphasized the need for precise biomarkers in schizophrenia to predict treatment courses effectively, lamenting the challenges faced due to the lack of such tools. Dr. Kumar explored Alzheimer's disease, highlighting the distinction between biomarkers and molecular targets, and critiqued the current reliance on amyloid-based treatments despite their limited clinical efficacy and significant side effects. Dr. Grisenda discussed the promises and pitfalls of using machine learning in biomarker discovery, stressing issues like data quality, validation, and the need for a structured approach to overcome current limitations. Finally, Dr. Nemerov provided a broader overview, noting the complexities of brain disorders and the challenges of developing meaningful biomarkers. He underscored the ethical considerations in biomarker use, such as privacy concerns and the implications of genetic testing. Nemerov pointed out that the complexity of the brain and psychiatric disorders requires a multifaceted approach, utilizing AI to handle the plethora of data, and suggested that while progress is slow, the future holds potential for breakthroughs in personalized psychiatry. The discussion touched upon biogenetic and psychosocial factors, emphasizing the interconnectedness of environmental and biological influences on mental health.

Keywords

biomarkers

psychiatry

schizophrenia

Alzheimer's disease

machine learning

treatment prediction

brain disorders

genetic testing

ethical considerations

personalized psychiatry

biogenetic factors

psychosocial factors